logo

SNOA

Sonoma Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
1.65 / 10
Underperform

Financial evaluation reveals subpar fundamentals, highlighted by negative asset-to-market value (-0.5007) and revenue-to-market value (-0.2574) differentials, along with a negative ROA (-24.3168). Only a few factors such as net profit margin and interest coverage ratio show marginal positives, but they are insufficient to offset the weaknesses. The overall fundamental score of 1.6/10 supports a defensive rating and underperformance outlook.

Fundamental(1.65)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score0/3
Weight19.53%
1M Return-3.84%
ROA (%)
Value-24.32
Score2/3
Weight2.06%
1M Return-0.39%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight8.95%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight12.63%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight21.81%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-24.32
Score2/3
Weight2.06%
1M Return-0.39%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight10.09%
1M Return-1.95%
Asset-MV
Value-0.50
Score2/3
Weight-10.50%
1M Return1.60%
Cash-MV
Value-0.07
Score1/3
Weight23.96%
1M Return-5.64%
Net profit / Total profit (%)
Value118.92
Score2/3
Weight9.40%
1M Return-1.71%
Is SNOA fundamentally strong?
  • SNOA scores 1.65/10 on fundamentals and holds a Premium valuation at present. Backed by its -43.30% ROE, -20.54% net margin, -1.48 P/E ratio, 1.36 P/B ratio, and -97.06% earnings growth, these metrics solidify its Underperform investment rating.